Study of Trilaciclib and Lurbinectidin
Study of Trilaciclib and Lurbinectidin
Recruiting · NCT05578326 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Trilaciclib and Lurbinectidin | Cytopenia, Hemic and Lymphatic Diseases, Neoplasms by Site, Thoracic Neoplasms, agranulocytosis, bronchial neoplasm, bronchogenic carcinoma, hematologic disorder, leukocyte disorder, leukopenia, lung cancer, lung disorder, lung neoplasm, neoplasm, neutropenia, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-09-21 | NCT05578326 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| G1 Therapeutics, Inc. | 2 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dartmouth Hitchcock Medical Center | Lebanon | United States | 79 |
| Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill | Chapel Hill | United States | 3 |